Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03763149 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas
A Phase 1 study, sponsored by Innovent Biologics (Suzhou) Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03763149 is a Phase 1 study that has completed, run by Innovent Biologics (Suzhou) Co.. The registered enrollment target is 20 participants.
The verdict
NCT03763149, a Phase 1 study, has completed, sponsored by Innovent Biologics (Suzhou) Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy in patients with advanced malignancies.
Interventions
- BIOLOGICAL IBI188
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-02-19 |
| Est. Completion | 2021-03-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03763149
The ClinicalTrials.gov registry entry for NCT03763149 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innovent Biologics (Suzhou) Co., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IBI188 is the first listed.
NCT03763149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03763149 about?
NCT03763149 is a clinical study titled "A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas". This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy in patients with advanced malignancies.
What is the current status of trial NCT03763149?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2019-02-19. Estimated completion is 2021-03-29.
What interventions are being tested in trial NCT03763149?
The interventions under investigation include: IBI188 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03763149?
This trial is sponsored by Innovent Biologics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.